Home > Journals > Minerva Cardiology and Angiology > Past Issues > Articles online first > Minerva Cardiology and Angiology 2022 Feb 25



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Cardiology and Angiology 2022 Feb 25

DOI: 10.23736/S2724-5683.22.05841-0


language: English

Smartphone and new tools for Atrial Fibrillation diagnosis: evidence for clinical applicability

Giovanni PAPACCIOLI 1, Giuseppe BASSI 1, Cecilia LUGI 2, Erika PARENTE 1, Antonello D’ANDREA 3, Riccardo PROIETTI 4, Egidio IMBALZANO 5, Ahmed ALTURKI 6, Vincenzo RUSSO 1

1 Department of Medical Translational Sciences, Monaldi Hospital, University of Campania Luigi Vanvitelli, Naples, Italy; 2 Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy; 3 Cardiology Unit, Umberto I Hospital, Nocera Inferiore, Salerno, Italy; 4 Liverpool center for cardiovascular science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK; 5 Department of Clinical and Experimental Medicine, University Hospital of Messina G. Martino, University of Messina, Messina, Italy; 6 Division of Cardiology, McGill University Health Center, Montreal, Canada


Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia in adults. AF increases the risk of heart failure, cardiac ischemic disease, dementia and Alzheimer’s disease. Either clinical and subclinical AF increase the risk of stroke and worsen the patients’ clinical outcome. The early diagnosis of AF episodes, even if asymptomatic or clinically silent, is of pivotal importance to ensure prompt and adequate thromboembolic risk prevention therapies. The development of technology is allowing new systematic mass screening possibilities, especially in patients with higher stroke risk. The mobile health devices available for AF detection are: smartphones, wristworn, earlobe sensors and handheld ECG. These devices showed a high accuracy in AF detection especially when a combined approach with single-Lead ECG and photoplethysmography algorithms is used. The use of wearable devices for AF screening is a feasible method but more head-to-head comparisons between mHealth and medical devices are needed to establish their comparative effectiveness across different study populations.

KEY WORDS: Subclinical atrial fibrillation; Wearable devices; Mobile health; iECG; Photoplethysmography

top of page